Targeted management of coexistent severe thrombophilias-A case report of a successful pregnancy despite paroxysmal nocturnal hemoglobinuria and hereditary protein C deficiency.

C5‐inhibitor anticoagulation breakthrough hemolysis complement activation complement inhibitor eculizumab paroxysmal nocturnal hemoglobinuria pregnancy thrombosis

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 14 02 2024
revised: 17 05 2024
accepted: 07 06 2024
medline: 17 10 2024
pubmed: 17 10 2024
entrez: 17 10 2024
Statut: epublish

Résumé

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by the absence of complement regulatory proteins on the surface of erythrocytes, leading to intravascular hemolysis and thrombosis. Managing PNH during pregnancy poses significant challenges due to increased risks of morbidity and mortality. This case report describes the detailed obstetric course of a 44-year-old woman with PNH and additional hereditary protein C deficiency who had previously experienced multiple thrombotic events and adverse pregnancy outcomes (two early miscarriages and one stillbirth at 25 weeks gestation [WG]), treated with eculizumab (terminal C5 inhibitor) and optimal anticoagulation management. Close monitoring of hemolysis and hemostasis parameters was conducted throughout the gestation period together with increased obstetrical surveillance. The pregnancy progressed without thrombotic complications or breakthrough hemolysis, and the patient delivered a healthy newborn at 36 WG after induction of labor due to restricted fetal growth. To the best of our knowledge, this is the first reported case of a positive pregnancy outcome despite PNH in conjunction with hereditary thrombophilia. This case report highlights the importance of a multidisciplinary approach involving hematologists and obstetricians in the management of pregnant women with PNH. Tailored therapy, close monitoring, and comprehensive care are crucial to minimize risks and optimize outcomes.

Identifiants

pubmed: 39415927
doi: 10.1002/jha2.972
pii: JHA2972
pmc: PMC11474299
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1048-1052

Informations de copyright

© 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

All the authors (J.D., M.G., L.A., F.G., M.G.) in this case report declare no conflicts of interest.

Auteurs

Julien Dereme (J)

Service and Central Laboratory of Haematology Department of Oncology and Department of Laboratories and Pathology Lausanne University Hospital (CHUV) and University of Lausanne (UNIL) Lausanne Switzerland.
Interregional Blood Transfusion SRC Epalinges Switzerland.

Matthew Goodyer (M)

Service of Haematology Valais Hospital Sion Switzerland.

David Baud (D)

Department Woman-Mother-Child Lausanne University Hospital University of Lausanne Lausanne Switzerland.

Lorenzo Alberio (L)

Service and Central Laboratory of Haematology Department of Oncology and Department of Laboratories and Pathology Lausanne University Hospital (CHUV) and University of Lausanne (UNIL) Lausanne Switzerland.

Francesco Grandoni (F)

Service and Central Laboratory of Haematology Department of Oncology and Department of Laboratories and Pathology Lausanne University Hospital (CHUV) and University of Lausanne (UNIL) Lausanne Switzerland.

Mathilde Gavillet (M)

Service and Central Laboratory of Haematology Department of Oncology and Department of Laboratories and Pathology Lausanne University Hospital (CHUV) and University of Lausanne (UNIL) Lausanne Switzerland.
Interregional Blood Transfusion SRC Epalinges Switzerland.

Classifications MeSH